Please assess the completion status of the following clinical trial:

Trial Title: Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must give consent to participate in the study and sign and date the IRB approved written informed consent form prior to the initiation of any study procedures~* Subject must be between the ages of 18 and 70~* Subject must have a diagnosis of bipolar I or II.~* Subject must be currently depressed as confirmed by the Mini-International Neuropsychiatric Interview (MINI)~* Subject must have a baseline Montgomery-Asberg Depression Scale (MADRS) score of \>19 and Young Mania Rating Scale (YMRS) score of \<12~* Women of childbearing potential must be nonpregnant/nonlactating and using adequate contraception if sexually active~* Subject must not be using any concomitant psychotropic medications during the acute phase except prn benzodiazepines~Exclusion Criteria:~* Subjects lacks the capacity to provide informed consent~* Subject has currently or previously used divalproex or Dvpx-ER~* Subject is a serious suicide risk or has medically unstable conditions as judged by the investigators~* Subject has any alcohol, cocaine, or cannabis dependence within 3 months of study entry~* Subject has any cocaine, hallucinogens, opiates, crystal methamphetamine, or MMDA abuse within 3 months of study entry

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Divalproex Sodium ER (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).